Definium Therapeutics Inc. shares rally as much as 60% Monday after late-stage trial data showed “groundbreaking” results in the psychedelic drug developer’s experimental treatment for major depressive disorders.
CryptoAlerta — análise de criptomoedas e mercado em tempo real